CEO of Aerie Pharmaceuticals provides a brief company overview at OIS meeting

Conference|ASRS

Vince Anido, Chairman & Chief Executive Officer of Aerie Pharmaceuticals, Inc., provides an update on the company's glaucoma drugs at the Ophthalmology Innovation Summit (OIS) meeting during the annual American Society of Retina Specialists (ASRS) conference in Vancouver, British Columbia, on July 20th, 2018.

Related Videos
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Quicker time to surgery affects VA outcomes in macula-on rhegmatogenous retinal detachments
Giant retinal tear-related detachments: Pediatric eyes repair better after vitrectomy with scleral buckling; adults only need vitrectomy
KALAHARI study: Phase 2 early results indicate alternative treatment pathway for patients with DME is effective, durable
Elevated albumin to creatinine ratio associated with central subfield thickness fluctuations in patients with DME
RGX-314 demonstrates DRSS improvements in patients with DME, NPDR
Related Content

ASRS 2022 recap: Significant strides in DME, AMD discussed among retina specialists

July 18th 2022

Putting in practice retina innovations amid a pandemic

August 28th 2020

New tool emerges for predicting the risk of vision loss from diabetic retinopathy

July 15th 2022

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020

TOWER study: A new index to measure retinal fluid fluctuations in the retina in wet AMD

July 15th 2022

Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuity

July 14th 2022

ASRS 2022 recap: Significant strides in DME, AMD discussed among retina specialists

July 18th 2022

Putting in practice retina innovations amid a pandemic

August 28th 2020

New tool emerges for predicting the risk of vision loss from diabetic retinopathy

July 15th 2022

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020

TOWER study: A new index to measure retinal fluid fluctuations in the retina in wet AMD

July 15th 2022

Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuity

July 14th 2022

ASRS 2022 recap: Significant strides in DME, AMD discussed among retina specialists

July 18th 2022

Putting in practice retina innovations amid a pandemic

August 28th 2020

New tool emerges for predicting the risk of vision loss from diabetic retinopathy

July 15th 2022

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020

TOWER study: A new index to measure retinal fluid fluctuations in the retina in wet AMD

July 15th 2022

Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuity

July 14th 2022
© 2023 MJH Life Sciences

All rights reserved.